智通财经APP获悉，今海医疗科技(02225)涨超11%，截至发稿，涨11.11%，报1.5港元，成交额385.56万港元。
消息面上，今海医疗科技近日公告称，其全资附属公司今海协寰近期与国药菱商订立销售总协议，据此，今海协寰授权国药菱商为集团若干高端医疗器械于中国的独家分销商，期限至今年10月。凭借国药菱商广泛的分销网络及强大的市场影响力，集团的主要产品可望于更广阔的市场上亮相，实现快速增长。特别是集团的4K3D 萤光内窥镜、椎间孔内窥镜及配套仪器包，已显示出强劲市场竞争力及增长潜力。
2024年上半年，今海医疗实现收益2593.7万新加坡元，同比增加116.45%。其中，来自微创手术解决方案及医疗产品和相关服务费的收益由2023年上半年的40万新加坡元增加至2024年上半年的1230万新加坡元。在技术储备方面，今海医疗拥有超过60项专利，商标超过20个，30多个在研项目。在“微创4.0时代”，今海医疗基础技术全面领先，已拥有的技术包括三/四芯片、裸眼3D、4K、3D以及荧光。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.